Northwest Biotherapeutics Seeks Antigen Deal To Avoid Folding

About one month after saying it would suspend recruitment in a Phase III trial of its lead prostate cancer drug, sell some fixed assets and consider other options for the future, Northwest Biotherapeutics Inc. has made more cuts and may shut down entirely. (BioWorld Today)